Abstract: The invention relates to aqueous polymer dispersions comprising polymerized units issued from the following monomers with related weight proportions based on 100 parts of weight of a)+b): a) 50 to 90% of a monoethylenically unsaturated non-ionic monomer, b) 10 to 50% of vinyl aromatic monomer or methyl methacrylate, c) 1 to 5% of a hydroxy-containing (meth)acrylate, d) 0.1 to 3% of acid monomer selected from d1) acid monomer selected from monocarboxylic or dicarboxylic acid monomers and d2) acid monomer selected from phosphorous-based or sulfur-based strong acid monomers or/and their salts, or from the mixtures of d1) and d2), e) 0.001 to 0.5% of chain transfer agent, and f) 0 to 1% one of internal crosslinker bearing at least two copolymerisable ethylenic unsaturations, the polymer having a Tg measured by DSC from ?30 to 0° C. and a gel content of 0 to 60%, formed during polymerization.

Abstract: Described is a method of determining a position of a mobile wireless device in a wireless communication network. The method comprises, for a plurality of clusters of transmission reception points (TRPs) associated with said mobile wireless device, measuring a parameter of first reference signals transmitted between said mobile wireless device and a single TRP from each cluster of TRPs. The method includes, based on the respective measured parameter of the first reference signals, selecting one cluster of TRPs from said plurality of clusters of TRPs. Position estimation information is determined from second reference signals transmitted between said mobile wireless device and a plurality of the TRPs comprising the selected cluster of TRPs. The determined position estimation information is used to determine a position for said mobile wireless device.

Abstract: A thermoplastic composition comprises particular amounts of a poly(phenylene ether)-poly(siloxane) block copolymer reaction product; a hydrogenated block copolymer of an alkenyl aromatic and a conjugated diene; tricalcium phosphate; and an organophosphate ester flame retardant. The composition can be particularly useful for use in battery pack insulation films or sheets.

Abstract: A package arrangement comprising a structure formed by a plurality of layers including an outer layer formed of a polymer material, one or more interior layers formed of a semi-aromatic polyamide composite material, and an inner layer formed of a polymer material, and an amount of water contained within the structure, the water including an amount of ozone dissolved therein, wherein the interior layer of the structure is configured to absorb oxygen and induce the degradation of the ozone.

Abstract: The present invention provides methods of treating and/or inhibiting cancer by administering a JAK1/2 inhibitor (e.g., ruxolitinib). The JAK1/2 inhibitor decreases expression of (or inhibits increased expression of) the checkpoint proteins PD-1, PD-L1, PD-L2, or B7 H3, and/or enhances T-cell killing of tumor cells, and/or enhances the anti-tumor effects of checkpoint inhibitors. The disclosed methods improve the efficacy of immune-based therapies used in treatment of cancer.

Abstract: A package arrangement comprising a structure formed by a plurality of layers including an outer layer formed of a polymer material, one or more interior layers formed of a semi-aromatic polyamide composite material, and an inner layer formed of a polymer material, and an amount of water contained within the structure, the water including an amount of ozone dissolved therein, wherein the interior layer of the structure is configured to absorb oxygen and induce the degradation of the ozone.

Abstract: The invention relates to aqueous polymer dispersions comprising polymerized units issued from the following monomers with related weight proportions based on 100 parts of weight of a)+b): a) 50 to 90% of a monoethylenically unsaturated non-ionic monomer, b) 10 to 50% of vinyl aromatic monomer or methyl methacrylate, c) 1 to 5% of a hydroxy-containing (meth)acrylate, d) 0.1 to 3% of acid monomer selected from d1) acid monomer selected from monocarboxylic or dicarboxylic acid monomers and d2) acid monomer selected from phosphorous-based or sulfur-based strong acid monomers or/and their salts, or from the mixtures of d1) and d2), e) 0.001 to 0.5% of chain transfer agent, and f) 0 to 1% one of internal crosslinker bearing at least two copolymerisable ethylenic unsaturations, the polymer having a Tg measured by DSC from ?30 to 0° C. and a gel content of 0 to 60%, formed during polymerization.

Abstract: The invention generally provides improved compositions and methods for detecting, diagnosing, prognosing, and monitoring multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in a subject. In particular, the invention provides methods for detecting BCMA in subjects to reliably diagnose, predict survival, or monitor multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in the subject.

Abstract: The invention generally provides improved compositions and methods for detecting, diagnosing, prognosing, and monitoring multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in a subject. In particular, the invention provides methods for detecting BCMA in subjects to reliably diagnose, predict survival, or monitor multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in the subject.

Abstract: Polyamide base resins with improved crystallization dynamics for the production of reinforced polyamide compositions having improved surface, shrink, warpage and mechanical properties such as toughness. The polyamide base resins are copolymers of polyamide 6 and polyamide 66, formed of ratios that are tailored to reduce the crystallization rate and final crystallization extent when used in melt processing to produce glass filled articles. The copolymers demonstrate improved polyamide morphology dynamics that in turn impart improved final properties in reinforced molded articles, such as improved surface finish, improved toughness/impact resistance, reduced warpage, and more symmetrical shrinkage properties.

Abstract: The invention generally provides improved compositions and methods for detecting, diagnosing, prognosing, and monitoring multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in a subject. In particular, the invention provides methods for detecting BCMA in subjects to reliably diagnose, predict survival, or monitor multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in the subject.

Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against TMEM154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages, wherein the cancer is relates to multiple myeloma, including multiple myeloma precursor diseases. This invention further relates to extracellular domains of TMEM154 proteins and variants, and therapeutic usages thereof.

Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against TMEM154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages, wherein the cancer is relates to multiple myeloma, including multiple myeloma precursor diseases. This invention further relates to extracellular domains of TMEM154 proteins and variants, and therapeutic usages thereof.

Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against TMEM154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages, wherein the cancer is relates to multiple myeloma, including multiple myeloma precursor diseases. This invention further relates to extracellular domains of TMEM154 proteins and variants, and therapeutic usages thereof.

Abstract: The present invention provides a coding gene having the nucleic acid sequence shown as SEQ ID NO:1 and the fusion protein RIG (SEQ ID NO:2) that inhibits osteoclast formation. The present invention also provides the preparation method for the fusion protein RIG as well as synthetic oligo-nucleotide primers, plasmids and host cells used in the method and a medicine having the above fusion protein RIG as active ingredient. The fusion protein RIG in present invention is derived from humanized immunoglobulin and RANKL with a flexible hinge region. RIG can cross link the cell surface receptor RANK and Fc? 1 to induce a cytosolic inhibitory signal leading to the inhibition of osteoclast formation. The fusion protein RIG in present invention can play an essential role in treating osteoporosis and bone resorption diseases caused by tumor metastasis.

Abstract: The present invention provides a coding gene having the nucleic acid sequence shown as SEQ ID NO:1 and the fusion protein RIG (SEQ ID NO:2) that inhibits osteoclast formation. The present invention also provides the preparation method for the fusion protein RIG as well as synthetic oligo-nucleotide primers, plasmids and host cells used in the method and a medicine having the above fusion protein RIG as active ingredient. The fusion protein RIG in present invention is derived from humanized immunoglobulin and RANKL with a flexible hinge region. RIG can cross link the cell surface receptor RANK and Fc? 1 to induce a cytosolic inhibitory signal leading to the inhibition of osteoclast formation. The fusion protein RIG in present invention can play an essential role in treating osteoporosis and bone resorption diseases caused by tumor metastasis.

Abstract: The present invention provides fusion proteins comprising an allergen sequence linked via an IgG hinge region to another polypeptide sequence capable of specifically binding to a native IgG inhibitory receptor containing an immune receptor tyrosine based inhibitory motif (ITIM). They are designed to cross-link an Fc receptor for IgE (e.g., Fc?R1) and an IgG inhibitory receptor (e.g., Fc?RIIb), thereby inhibiting the IgE-driven mediators released from mast cells and basophils. In addition, the present invention provides nucleic acid molecules encoding the fusion proteins, vectors and host cells for producing the fusion proteins, pharmaceutical compositions comprising the fusion proteins, and methods for ameliorating or reducing the risk of IgE-medicated allergic diseases.